APO Research
Talk to an analyst

APO RESEARCH · REPORT

C Difficile Infection Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

C Difficile Infection Drug Industry Research Report 2026

22 December 2025132 pages

Choose your research edition.

Industry ResearchC Difficile Infection Drug Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal C Difficile Infection Drug Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal C Difficile Infection Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal C Difficile Infection Drug Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal C Difficile Infection Drug Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global C Difficile Infection Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for C Difficile Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for C Difficile Infection Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for C Difficile Infection Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of C Difficile Infection Drug include Zhejiang Medicine, Sanofi, Merck, Eli Lilly, Pfizer, Fresenius, AstraZeneca, Xellia and Strides, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global C Difficile Infection Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k tons) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

C Difficile Infection Drug Market by Company

Zhejiang Medicine

Sanofi

Merck

Eli Lilly

Pfizer

Fresenius

AstraZeneca

Xellia

Strides

Merus labs

Lupin

Flynn Pharma

Astellas

Aspen Pharmacare

ANI Pharmaceutical

Akorn

C Difficile Infection Drug Segment by Type

Fidaxomycin

Metronidazole

Vancomycin

Others

C Difficile Infection Drug Segment by Application

Pre-treatment

Mid-term treatment

Others

C Difficile Infection Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global C Difficile Infection Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of C Difficile Infection Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of C Difficile Infection Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of C Difficile Infection Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of C Difficile Infection Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of C Difficile Infection Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global C Difficile Infection Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global C Difficile Infection Drug Sales (k tons) of Manufacturers (2021-2026) Table 7. Global C Difficile Infection Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global C Difficile Infection Drug Revenue of Manufacturers (2021-2026) Table 9. Global C Difficile Infection Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market C Difficile Infection Drug Average Price (US$/ton) of Manufacturers (2021-2026) Table 11. Global C Difficile Infection Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of C Difficile Infection Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of C Difficile Infection Drug, Product Type & Application Table 14. Global C Difficile Infection Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global C Difficile Infection Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Zhejiang Medicine Company Information Table 19. Zhejiang Medicine Business Overview Table 20. Zhejiang Medicine C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 21. Zhejiang Medicine C Difficile Infection Drug Product Portfolio Table 22. Zhejiang Medicine Recent Developments Table 23. Sanofi Company Information Table 24. Sanofi Business Overview Table 25. Sanofi C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 26. Sanofi C Difficile Infection Drug Product Portfolio Table 27. Sanofi Recent Developments Table 28. Merck Company Information Table 29. Merck Business Overview Table 30. Merck C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 31. Merck C Difficile Infection Drug Product Portfolio Table 32. Merck Recent Developments Table 33. Eli Lilly Company Information Table 34. Eli Lilly Business Overview Table 35. Eli Lilly C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 36. Eli Lilly C Difficile Infection Drug Product Portfolio Table 37. Eli Lilly Recent Developments Table 38. Pfizer Company Information Table 39. Pfizer Business Overview Table 40. Pfizer C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 41. Pfizer C Difficile Infection Drug Product Portfolio Table 42. Pfizer Recent Developments Table 43. Fresenius Company Information Table 44. Fresenius Business Overview Table 45. Fresenius C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 46. Fresenius C Difficile Infection Drug Product Portfolio Table 47. Fresenius Recent Developments Table 48. AstraZeneca Company Information Table 49. AstraZeneca Business Overview Table 50. AstraZeneca C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 51. AstraZeneca C Difficile Infection Drug Product Portfolio Table 52. AstraZeneca Recent Developments Table 53. Xellia Company Information Table 54. Xellia Business Overview Table 55. Xellia C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 56. Xellia C Difficile Infection Drug Product Portfolio Table 57. Xellia Recent Developments Table 58. Strides Company Information Table 59. Strides Business Overview Table 60. Strides C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 61. Strides C Difficile Infection Drug Product Portfolio Table 62. Strides Recent Developments Table 63. Merus labs Company Information Table 64. Merus labs Business Overview Table 65. Merus labs C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 66. Merus labs C Difficile Infection Drug Product Portfolio Table 67. Merus labs Recent Developments Table 68. Lupin Company Information Table 69. Lupin Business Overview Table 70. Lupin C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 71. Lupin C Difficile Infection Drug Product Portfolio Table 72. Lupin Recent Developments Table 73. Flynn Pharma Company Information Table 74. Flynn Pharma Business Overview Table 75. Flynn Pharma C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 76. Flynn Pharma C Difficile Infection Drug Product Portfolio Table 77. Flynn Pharma Recent Developments Table 78. Astellas Company Information Table 79. Astellas Business Overview Table 80. Astellas C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 81. Astellas C Difficile Infection Drug Product Portfolio Table 82. Astellas Recent Developments Table 83. Aspen Pharmacare Company Information Table 84. Aspen Pharmacare Business Overview Table 85. Aspen Pharmacare C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 86. Aspen Pharmacare C Difficile Infection Drug Product Portfolio Table 87. Aspen Pharmacare Recent Developments Table 88. ANI Pharmaceutical Company Information Table 89. ANI Pharmaceutical Business Overview Table 90. ANI Pharmaceutical C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 91. ANI Pharmaceutical C Difficile Infection Drug Product Portfolio Table 92. ANI Pharmaceutical Recent Developments Table 93. Akorn Company Information Table 94. Akorn Business Overview Table 95. Akorn C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 96. Akorn C Difficile Infection Drug Product Portfolio Table 97. Akorn Recent Developments Table 98. Global C Difficile Infection Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 99. Global C Difficile Infection Drug Sales by Region (2021-2026) & (k tons) Table 100. Global C Difficile Infection Drug Sales Market Share by Region (2021-2026) Table 101. Global C Difficile Infection Drug Sales by Region (2027-2032) & (k tons) Table 102. Global C Difficile Infection Drug Sales Market Share by Region (2027-2032) Table 103. Global C Difficile Infection Drug Revenue by Region (2021-2026) & (US$ Million) Table 104. Global C Difficile Infection Drug Revenue Market Share by Region (2021-2026) Table 105. Global C Difficile Infection Drug Revenue by Region (2027-2032) & (US$ Million) Table 106. Global C Difficile Infection Drug Revenue Market Share by Region (2027-2032) Table 107. North America C Difficile Infection Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. North America C Difficile Infection Drug Sales by Country (2021-2026) & (k tons) Table 109. North America C Difficile Infection Drug Sales by Country (2027-2032) & (k tons) Table 110. North America C Difficile Infection Drug Revenue by Country (2021-2026) & (US$ Million) Table 111. North America C Difficile Infection Drug Revenue by Country (2027-2032) & (US$ Million) Table 112. Europe C Difficile Infection Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Europe C Difficile Infection Drug Sales by Country (2021-2026) & (k tons) Table 114. Europe C Difficile Infection Drug Sales by Country (2027-2032) & (k tons) Table 115. Europe C Difficile Infection Drug Revenue by Country (2021-2026) & (US$ Million) Table 116. Europe C Difficile Infection Drug Revenue by Country (2027-2032) & (US$ Million) Table 117. Asia Pacific C Difficile Infection Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Asia Pacific C Difficile Infection Drug Sales by Country (2021-2026) & (k tons) Table 119. Asia Pacific C Difficile Infection Drug Sales by Country (2027-2032) & (k tons) Table 120. Asia Pacific C Difficile Infection Drug Revenue by Country (2021-2026) & (US$ Million) Table 121. Asia Pacific C Difficile Infection Drug Revenue by Country (2027-2032) & (US$ Million) Table 122. South America C Difficile Infection Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. South America C Difficile Infection Drug Sales by Country (2021-2026) & (k tons) Table 124. South America C Difficile Infection Drug Sales by Country (2027-2032) & (k tons) Table 125. South America C Difficile Infection Drug Revenue by Country (2021-2026) & (US$ Million) Table 126. South America C Difficile Infection Drug Revenue by Country (2027-2032) & (US$ Million) Table 127. Middle East and Africa C Difficile Infection Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Middle East and Africa C Difficile Infection Drug Sales by Country (2021-2026) & (k tons) Table 129. Middle East and Africa C Difficile Infection Drug Sales by Country (2027-2032) & (k tons) Table 130. Middle East and Africa C Difficile Infection Drug Revenue by Country (2021-2026) & (US$ Million) Table 131. Middle East and Africa C Difficile Infection Drug Revenue by Country (2027-2032) & (US$ Million) Table 132. Global C Difficile Infection Drug Sales by Type (2021-2026) & (k tons) Table 133. Global C Difficile Infection Drug Sales by Type (2027-2032) & (k tons) Table 134. Global C Difficile Infection Drug Sales Market Share by Type (2021-2026) Table 135. Global C Difficile Infection Drug Sales Market Share by Type (2027-2032) Table 136. Global C Difficile Infection Drug Revenue by Type (2021-2026) & (US$ Million) Table 137. Global C Difficile Infection Drug Revenue by Type (2027-2032) & (US$ Million) Table 138. Global C Difficile Infection Drug Revenue Market Share by Type (2021-2026) Table 139. Global C Difficile Infection Drug Revenue Market Share by Type (2027-2032) Table 140. Global C Difficile Infection Drug Price by Type (2021-2026) & (US$/ton) Table 141. Global C Difficile Infection Drug Price by Type (2027-2032) & (US$/ton) Table 142. Global C Difficile Infection Drug Sales by Application (2021-2026) & (k tons) Table 143. Global C Difficile Infection Drug Sales by Application (2027-2032) & (k tons) Table 144. Global C Difficile Infection Drug Sales Market Share by Application (2021-2026) Table 145. Global C Difficile Infection Drug Sales Market Share by Application (2027-2032) Table 146. Global C Difficile Infection Drug Revenue by Application (2021-2026) & (US$ Million) Table 147. Global C Difficile Infection Drug Revenue by Application (2027-2032) & (US$ Million) Table 148. Global C Difficile Infection Drug Revenue Market Share by Application (2021-2026) Table 149. Global C Difficile Infection Drug Revenue Market Share by Application (2027-2032) Table 150. Global C Difficile Infection Drug Price by Application (2021-2026) & (US$/ton) Table 151. Global C Difficile Infection Drug Price by Application (2027-2032) & (US$/ton) Table 152. Key Raw Materials Table 153. Raw Materials Key Suppliers Table 154. C Difficile Infection Drug Distributors List Table 155. C Difficile Infection Drug Customers List Table 156. C Difficile Infection Drug Industry Trends Table 157. C Difficile Infection Drug Industry Drivers Table 158. C Difficile Infection Drug Industry Restraints Table 159. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. C Difficile Infection Drug Product Image Figure 5. Global C Difficile Infection Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global C Difficile Infection Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global C Difficile Infection Drug Sales (2021-2032) & (k tons) Figure 8. Global C Difficile Infection Drug Average Price (US$/ton) & (2021-2032) Figure 9. Fidaxomycin Product Image Figure 10. Metronidazole Product Image Figure 11. Vancomycin Product Image Figure 12. Others Product Image Figure 13. Pre-treatment Product Image Figure 14. Mid-term treatment Product Image Figure 15. Others Product Image Figure 16. Global C Difficile Infection Drug Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of C Difficile Infection Drug, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 C Difficile Infection Drug Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global C Difficile Infection Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global C Difficile Infection Drug Sales by Region in 2025 Figure 22. Global C Difficile Infection Drug Revenue by Region in 2025 Figure 23. North America C Difficile Infection Drug Market Size by Country in 2025 Figure 24. North America C Difficile Infection Drug Sales Market Share by Country (2021-2032) Figure 25. North America C Difficile Infection Drug Revenue Market Share by Country (2021-2032) Figure 26. United States C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe C Difficile Infection Drug Market Size by Country in 2025 Figure 30. Europe C Difficile Infection Drug Sales Market Share by Country (2021-2032) Figure 31. Europe C Difficile Infection Drug Revenue Market Share by Country (2021-2032) Figure 32. Germany C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific C Difficile Infection Drug Market Size by Country in 2025 Figure 43. Asia Pacific C Difficile Infection Drug Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific C Difficile Infection Drug Revenue Market Share by Country (2021-2032) Figure 45. China C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America C Difficile Infection Drug Market Size by Country in 2025 Figure 54. South America C Difficile Infection Drug Sales Market Share by Country (2021-2032) Figure 55. South America C Difficile Infection Drug Revenue Market Share by Country (2021-2032) Figure 56. Brazil C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa C Difficile Infection Drug Market Size by Country in 2025 Figure 60. Middle East and Africa C Difficile Infection Drug Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa C Difficile Infection Drug Revenue Market Share by Country (2021-2032) Figure 62. Egypt C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries C Difficile Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global C Difficile Infection Drug Sales Market Share by Type (2021-2032) Figure 68. Global C Difficile Infection Drug Revenue Market Share by Type (2021-2032) Figure 69. Global C Difficile Infection Drug Price (US$/ton) by Type (2021-2032) Figure 70. Global C Difficile Infection Drug Sales Market Share by Application (2021-2032) Figure 71. Global C Difficile Infection Drug Revenue Market Share by Application (2021-2032) Figure 72. Global C Difficile Infection Drug Price (US$/ton) by Application (2021-2032) Figure 73. C Difficile Infection Drug Value Chain Figure 74. C Difficile Infection Drug Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. C Difficile Infection Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Fidaxomycin
  • Metronidazole
  • Vancomycin
  • Others
Applications
  • Pre-treatment
  • Mid-term treatment
  • Others
Companies covered
  • Zhejiang Medicine
  • Sanofi
  • Merck
  • Eli Lilly
  • Pfizer
  • Fresenius
  • AstraZeneca
  • Xellia
  • Strides
  • Merus labs
  • Lupin
  • Flynn Pharma
  • Astellas
  • Aspen Pharmacare
  • ANI Pharmaceutical
  • Akorn

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global C Difficile Infection Drug Market Size (2021-2032)
  4. 2.2.2 Global C Difficile Infection Drug Sales (2021-2032)
  5. 2.2.3 Global C Difficile Infection Drug Market Average Price (2021-2032)
  6. 2.3 C Difficile Infection Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Fidaxomycin
  9. 2.3.3 Metronidazole
  10. 2.3.4 Vancomycin
  11. 2.3.5 Others
  12. 2.4 C Difficile Infection Drug by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Pre-treatment
  15. 2.4.3 Mid-term treatment
  16. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global C Difficile Infection Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global C Difficile Infection Drug Sales (k tons) of Manufacturers (2021-2026)
  3. 3.3 Global C Difficile Infection Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global C Difficile Infection Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global C Difficile Infection Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of C Difficile Infection Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of C Difficile Infection Drug, Product Type & Application
  8. 3.8 Global Manufacturers of C Difficile Infection Drug, Established Date
  9. 3.9 Global C Difficile Infection Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Zhejiang Medicine
  2. 4.1.1 Zhejiang Medicine Company Information
  3. 4.1.2 Zhejiang Medicine Business Overview
  4. 4.1.3 Zhejiang Medicine C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Zhejiang Medicine C Difficile Infection Drug Product Portfolio
  6. 4.1.5 Zhejiang Medicine Recent Developments
  7. 4.2 Sanofi
  8. 4.2.1 Sanofi Company Information
  9. 4.2.2 Sanofi Business Overview
  10. 4.2.3 Sanofi C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sanofi C Difficile Infection Drug Product Portfolio
  12. 4.2.5 Sanofi Recent Developments
  13. 4.3 Merck
  14. 4.3.1 Merck Company Information
  15. 4.3.2 Merck Business Overview
  16. 4.3.3 Merck C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Merck C Difficile Infection Drug Product Portfolio
  18. 4.3.5 Merck Recent Developments
  19. 4.4 Eli Lilly
  20. 4.4.1 Eli Lilly Company Information
  21. 4.4.2 Eli Lilly Business Overview
  22. 4.4.3 Eli Lilly C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Eli Lilly C Difficile Infection Drug Product Portfolio
  24. 4.4.5 Eli Lilly Recent Developments
  25. 4.5 Pfizer
  26. 4.5.1 Pfizer Company Information
  27. 4.5.2 Pfizer Business Overview
  28. 4.5.3 Pfizer C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Pfizer C Difficile Infection Drug Product Portfolio
  30. 4.5.5 Pfizer Recent Developments
  31. 4.6 Fresenius
  32. 4.6.1 Fresenius Company Information
  33. 4.6.2 Fresenius Business Overview
  34. 4.6.3 Fresenius C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Fresenius C Difficile Infection Drug Product Portfolio
  36. 4.6.5 Fresenius Recent Developments
  37. 4.7 AstraZeneca
  38. 4.7.1 AstraZeneca Company Information
  39. 4.7.2 AstraZeneca Business Overview
  40. 4.7.3 AstraZeneca C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 AstraZeneca C Difficile Infection Drug Product Portfolio
  42. 4.7.5 AstraZeneca Recent Developments
  43. 4.8 Xellia
  44. 4.8.1 Xellia Company Information
  45. 4.8.2 Xellia Business Overview
  46. 4.8.3 Xellia C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Xellia C Difficile Infection Drug Product Portfolio
  48. 4.8.5 Xellia Recent Developments
  49. 4.9 Strides
  50. 4.9.1 Strides Company Information
  51. 4.9.2 Strides Business Overview
  52. 4.9.3 Strides C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Strides C Difficile Infection Drug Product Portfolio
  54. 4.9.5 Strides Recent Developments
  55. 4.10 Merus labs
  56. 4.10.1 Merus labs Company Information
  57. 4.10.2 Merus labs Business Overview
  58. 4.10.3 Merus labs C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Merus labs C Difficile Infection Drug Product Portfolio
  60. 4.10.5 Merus labs Recent Developments
  61. 4.11 Lupin
  62. 4.11.1 Lupin Company Information
  63. 4.11.2 Lupin Business Overview
  64. 4.11.3 Lupin C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Lupin C Difficile Infection Drug Product Portfolio
  66. 4.11.5 Lupin Recent Developments
  67. 4.12 Flynn Pharma
  68. 4.12.1 Flynn Pharma Company Information
  69. 4.12.2 Flynn Pharma Business Overview
  70. 4.12.3 Flynn Pharma C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Flynn Pharma C Difficile Infection Drug Product Portfolio
  72. 4.12.5 Flynn Pharma Recent Developments
  73. 4.13 Astellas
  74. 4.13.1 Astellas Company Information
  75. 4.13.2 Astellas Business Overview
  76. 4.13.3 Astellas C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Astellas C Difficile Infection Drug Product Portfolio
  78. 4.13.5 Astellas Recent Developments
  79. 4.14 Aspen Pharmacare
  80. 4.14.1 Aspen Pharmacare Company Information
  81. 4.14.2 Aspen Pharmacare Business Overview
  82. 4.14.3 Aspen Pharmacare C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Aspen Pharmacare C Difficile Infection Drug Product Portfolio
  84. 4.14.5 Aspen Pharmacare Recent Developments
  85. 4.15 ANI Pharmaceutical
  86. 4.15.1 ANI Pharmaceutical Company Information
  87. 4.15.2 ANI Pharmaceutical Business Overview
  88. 4.15.3 ANI Pharmaceutical C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 ANI Pharmaceutical C Difficile Infection Drug Product Portfolio
  90. 4.15.5 ANI Pharmaceutical Recent Developments
  91. 4.16 Akorn
  92. 4.16.1 Akorn Company Information
  93. 4.16.2 Akorn Business Overview
  94. 4.16.3 Akorn C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Akorn C Difficile Infection Drug Product Portfolio
  96. 4.16.5 Akorn Recent Developments
5 Global C Difficile Infection Drug Market Scenario by Region
  1. 5.1 Global C Difficile Infection Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global C Difficile Infection Drug Sales by Region: 2021-2032
  3. 5.2.1 Global C Difficile Infection Drug Sales by Region: 2021-2026
  4. 5.2.2 Global C Difficile Infection Drug Sales by Region: 2027-2032
  5. 5.3 Global C Difficile Infection Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global C Difficile Infection Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global C Difficile Infection Drug Revenue by Region: 2027-2032
  8. 5.4 North America C Difficile Infection Drug Market Facts & Figures by Country
  9. 5.4.1 North America C Difficile Infection Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America C Difficile Infection Drug Sales by Country (2021-2032)
  11. 5.4.3 North America C Difficile Infection Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe C Difficile Infection Drug Market Facts & Figures by Country
  16. 5.5.1 Europe C Difficile Infection Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe C Difficile Infection Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe C Difficile Infection Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific C Difficile Infection Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific C Difficile Infection Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific C Difficile Infection Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific C Difficile Infection Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America C Difficile Infection Drug Market Facts & Figures by Country
  41. 5.7.1 South America C Difficile Infection Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America C Difficile Infection Drug Sales by Country (2021-2032)
  43. 5.7.3 South America C Difficile Infection Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa C Difficile Infection Drug Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa C Difficile Infection Drug Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa C Difficile Infection Drug Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa C Difficile Infection Drug Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global C Difficile Infection Drug Sales by Type (2021-2032)
  2. 6.1.1 Global C Difficile Infection Drug Sales by Type (2021-2032) & (k tons)
  3. 6.1.2 Global C Difficile Infection Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global C Difficile Infection Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global C Difficile Infection Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global C Difficile Infection Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global C Difficile Infection Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global C Difficile Infection Drug Sales by Application (2021-2032)
  2. 7.1.1 Global C Difficile Infection Drug Sales by Application (2021-2032) & (k tons)
  3. 7.1.2 Global C Difficile Infection Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global C Difficile Infection Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global C Difficile Infection Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global C Difficile Infection Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global C Difficile Infection Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 C Difficile Infection Drug Value Chain Analysis
  2. 8.1.1 C Difficile Infection Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 C Difficile Infection Drug Production Mode & Process
  5. 8.2 C Difficile Infection Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 C Difficile Infection Drug Distributors
  8. 8.2.3 C Difficile Infection Drug Customers
9 Global C Difficile Infection Drug Analyzing Market Dynamics
  1. 9.1 C Difficile Infection Drug Industry Trends
  2. 9.2 C Difficile Infection Drug Industry Drivers
  3. 9.3 C Difficile Infection Drug Industry Opportunities and Challenges
  4. 9.4 C Difficile Infection Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst